Werewolf Therapeutics Inc...

0.91
0.06 (6.51%)
At close: Apr 24, 2025, 3:59 PM
0.89
-2.51%
After-hours: Apr 24, 2025, 04:38 PM EDT

Werewolf Therapeutics Statistics

Share Statistics

Werewolf Therapeutics has 44.83M shares outstanding. The number of shares has increased by 3.16% in one year.

Shares Outstanding 44.83M
Shares Change (YoY) 3.16%
Shares Change (QoQ) 0.59%
Owned by Institutions (%) 64.45%
Shares Floating 33.13M
Failed to Deliver (FTD) Shares 62
FTD / Avg. Volume 0.02%

Short Selling Information

The latest short interest is 1.96M, so 4.37% of the outstanding shares have been sold short.

Short Interest 1.96M
Short % of Shares Out 4.37%
Short % of Float 7.33%
Short Ratio (days to cover) 7.88

Valuation Ratios

The PE ratio is -0.91 and the forward PE ratio is -0.57. Werewolf Therapeutics's PEG ratio is -0.02.

PE Ratio -0.91
Forward PE -0.57
PS Ratio 34.02
Forward PS 0.2
PB Ratio 0.87
P/FCF Ratio -1.14
PEG Ratio -0.02
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Werewolf Therapeutics.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 7.45, with a Debt / Equity ratio of 0.15.

Current Ratio 7.45
Quick Ratio 7.45
Debt / Equity 0.15
Debt / EBITDA -0.17
Debt / FCF -0.19
Interest Coverage -15.81

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $40.98K
Profits Per Employee $-1.53M
Employee Count 46
Asset Turnover 0.01
Inventory Turnover n/a

Taxes

Income Tax 0
Effective Tax Rate 0%

Stock Price Statistics

The stock price has increased by -85.35% in the last 52 weeks. The beta is 0.48, so Werewolf Therapeutics's price volatility has been higher than the market average.

Beta 0.48
52-Week Price Change -85.35%
50-Day Moving Average 1.08
200-Day Moving Average 1.79
Relative Strength Index (RSI) 48.88
Average Volume (20 Days) 258.54K

Income Statement

In the last 12 months, Werewolf Therapeutics had revenue of 1.89M and earned -70.52M in profits. Earnings per share was -1.63.

Revenue 1.89M
Gross Profit 1.89M
Operating Income -73.59M
Net Income -70.52M
EBITDA -64.05M
EBIT -65.86M
Earnings Per Share (EPS) -1.63
Full Income Statement

Balance Sheet

The company has 112.22M in cash and 10.99M in debt, giving a net cash position of 101.22M.

Cash & Cash Equivalents 112.22M
Total Debt 10.99M
Net Cash 101.22M
Retained Earnings -414.59M
Total Assets 126.93M
Working Capital 97.89M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -56.19M and capital expenditures -254K, giving a free cash flow of -56.44M.

Operating Cash Flow -56.19M
Capital Expenditures -254K
Free Cash Flow -56.44M
FCF Per Share -1.3
Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -3904.19% and -3740.85%.

Gross Margin 100%
Operating Margin -3904.19%
Pretax Margin -3740.85%
Profit Margin -3740.85%
EBITDA Margin -3397.61%
EBIT Margin -3904.19%
FCF Margin -2994.27%

Dividends & Yields

HOWL does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for HOWL is $8, which is 779.1% higher than the current price. The consensus rating is "Buy".

Price Target $8
Price Target Difference 779.1%
Analyst Consensus Buy
Analyst Count 3
Stock Forecasts

Scores

Altman Z-Score -4.95
Piotroski F-Score 3